{"schema_version":"secwatch.filing_event.v1","accession":"0001437402-25-000016","form_type":"8-K","ticker":"ARDX","cik":"0001437402","company_name":"ARDELYX, INC.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.412384+00:00","generated_at":"2026-05-17T01:17:56.771572+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ardelyx Q3 2025: product revenue $105.5M, IBSRELA +92% YoY, guidance raised","bullets":["Total Q3 product revenue $105.5M (+15% YoY); net loss $1.0M ($0.00 per share).","IBSRELA revenue $78.2M (+92% YoY, +20% QoQ); 2025 guidance raised to $270-275M.","XPHOZAH revenue $27.4M (+9% QoQ); YoY decline due to loss of Part D coverage.","Cash $242.7M; new NHE3 inhibitor RDX10531 with IND submission targeted for 2026.","Appointed Sue Hohenleitner as CFO effective Nov 4, plus new CMO and CTO in Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0001437402-25-000016","json":"https://secwatch.observer/filing/0001437402-25-000016.json","markdown":"https://secwatch.observer/filing/0001437402-25-000016.md","text":"https://secwatch.observer/filing/0001437402-25-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437402/000143740225000016/0001437402-25-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437402/000143740225000016/ardx-20251030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:17:56.771572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}